Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 7, 2008, Pages 2486-2496

  Louie, A ^a   Heine, H S ^b   Kim, K ^a   Brown, D L ^a   VanScoy, B ^a   Liu, W ^a   Kinzig Schippers, M ^c   Sorgel F ^c   Drusano, G L ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c Institute for Biomedical and Pharmaceutical Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LINEZOLID;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACILLUS ANTHRACIS; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG EXPOSURE; IN VITRO STUDY; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL;

ACETAMIDES; ANTHRAX; ANTI-BACTERIAL AGENTS; BACILLUS ANTHRACIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; HUMANS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; MUTATION; OXAZOLIDINONES;

EID: 46249110625     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01439-07     Document Type: Article

References (39)

1. Andes, D., M. L. van Ogtrop, J. Peng, and W. A. Craig. 2002. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob. Agents Chemother. 46:3484-3489.
2. Bishop, E., S. Melvani, B. P. Howden, P. G. P. Charles, and M. L. Grayson. 2006. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob. Agents Chemother. 50:1599-1602.
3. Boak, L. M., J. Li, C. R. Rayner, and R. L. Nation. 2007. Pharmacokinetic/ pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model. Antimicrob. Agents Chemother. 51:1287-1292.
4. Bush, L. M., B. H. Abrams, A. Beall, and C. C. Johnson. 2001. Index case of fatal inhalational anthrax due to bioterrorism in the United States. N. Engl. J. Med. 345:1607-1610.
5. Centers for Disease Control and Prevention. 2001. Evaluation of Bacillus anthracis contamination inside the Brentwood mail processing and distribution center, District of Columbia. MMWR Morb. Mortal. Wkly. Rep. 50: 1129-1132.
6. Centers for Disease Control and Prevention. 2002. Evaluation of postexposure antibiotic prophylaxis to prevent anthrax. MMWR Morb. Mortal. Wkly. Rep. 51:59.
7. Centers for Disease Control and Prevention. 2001. Update: investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb. Mortal. Wkly. Rep. 50:909-919.
8. Clinical Laboratory Standards Institute. 2006. Document M7-A7. Methods for dilutional antimicrobial susceptibility testing for bacteria that grow aerobically; approved standard, 7th ed. Clinical Laboratory Standards Institute, Wayne, PA.
9. D'Argenio, D. Z., and A. Schumitzk. 1997. ADAPT II. A program for simulation, identification, and optimal experimental design. User manual. Biomedical Simulations Resource, University of Southern California, Los Angeles, CA. http://bmsr.usc.edu/.
10. Deziel, M. R., H. Heine, A. Louie, M. Kao, W. R. Byrne, J. Basset, L. Miller, K. Bush, M. Kelly, and G. L. Drusano. 2005. Identification of effective antimicrobial regimens for use in humans for the therapy of Bacillus anthracis infections and postexposure prophylaxis. Antimicrob. Agents Chemother. 49:5099-5106.
11. Drusano, G. L., J. A. Bilello, S. L. Preston, E. O'Mara, S. Kaul, S. Schnittman, and R. Echols. 2001. Hollow fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable. J. Infect. Dis. 183:1126-1129.
12. Drusano, G. L., P. A. Bilello, W. T. Symonds, D. S. Stein, J. McDowell, A. Bye, and J. A. Bilello. 2002. Pharmacodynamics of abacavir in an in vitro hollow-fiber model system. Antimicrob. Agents Chemother. 46:464-470.
13. Greene, C. M., J. Reefhuuis, C. Tan, A. E. Fiore, S. Goldstein, M. J. Beach, S. C. Redd, D. Valiante, G. Burr, J. Buehler, R. W. Pinner, E. Bresnitz, B. P. Bell, et al. 2002. Epidemiologic investigations of bioterrorism-related anthrax, New Jersey, 2001. Emerg. Infect. Dis. 8:1048-1055.
14. Gumbo, T., A. Louie, W. Liu, D. Brown, P. G. Ambrose, S. M. Bhavnani, and G. L. Drusano. 2007. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob. Agents Chemother. 51: 2329-2336.
15. Inglesby, T., T. O'Toole, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. M. Friedlander, J. Gerberding, J. Hauser, J. Hughes, J. McDade, M. T. Osterholm, G. Parker, T. M. Perl, P. K. Russell, K. Tonat, et al. 2002. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287:2236-2252.
16. Jernigan, J. A., D. S. Stephen, D. A. Ashford, C. Omenaca, M. S. Topiel, M. Galbraith, M. Tapper, T. L. Fisk, S. Zaki, T. Popovic, R. F. Meyer, C. P. Quinn, S. A. Harper, S. K. Fridkin, J. J. Sejvar, C. W. Shepard, M. McConnell, J. Gaumer, W. J. Shieh, J. M. Malecki, J. L. Gerberding, J. M. Hughes, B. A. Perkins, et al. 2001. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg. Infect. Dis. 7:933-944.
17. Kao, L. M., K. Bush, R. Barnewell, J. Estep, F. W. Thalacker, P. H. Olson, G. L. Drusano, N., Minton, S. Chien, A. Hemeryck, and M. F. Kelley. 2006. Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model. Antimicrob. Agents Chemother. 50:3535-3542.
18. Leary, R., R. Jelliffe, S. Schumitzky, and M. Van Guilder. 2001. An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD) models, p.389-394. Proc. 14th IEEE Sympos. Computer-Based Med. Syst. IEEE Computer Society, Bethesda, MD.
19. Lee, E., S. Burger, J. Shah, C. Melton, M. Mullen, F. Warren, and R. Press. 2003. Linezolid-associated toxic optic neutropathy; a report of 2 cases. Clin. Infect. Dis. 37:1389-1391.
20. Li, J., C. R. Rayner, S. Dixson, and R. L. Nation. 2004. Simple method for the assay of linezolid in brain heart infusion broth by high-performance liquid chromatography. Biomed. Chromatogr. 18:1-5.
21. Louie, A., M. R. Deziel, W. Liu, and G. L. Drusano. 2007. Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy. Antimicrob. Agents Chemother. 51:2661-2667.
22. Louie, A., K. Kim, D. Brown, B. VanScoy, R. Kulawy, W. Liu, M. Kinzig-Schippers, F. Sorgel, H. S. Heine, and G. L. Drusano. 2007. Dose-ranging and dose-fractionation studies of moxifloxacin against Bacillus anthracis, abstr. A-1442, p.36. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., 2007.
23. Louie, A., K. Kim, D. Brown, B. VanScoy, R. Kulawy, V. Hsu, C. Fregeau, A. Ardzinski, F. Sorgel, H. S. Heine, and G. L. Drusano. 2007. Impact of spores on the rate of kill of Bacillus anthracis for five different antibiotics in a hollow fiber system, abstr. A-1436, p.34. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., 2007.
24. Louie, A., W. Liu, M. Deziel, M. Drusano, and G. Drusano. 2004. Pharmacodynamics of linezolid in a neutropenic mouse thigh model of Staphylococcus aureus infection, abstr. A-1865. Abstr. 44th Intersci. Conf. Antimicrob. Agents Chemother., 2004.
25. Meagher, A. K., A. Forrest, C. R. Rayner, M. C. Birmingham, and J. J. Schentag. 2003. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob. Agents Chemother. 47:548-553.
26. Meka, V. G., S. K. Pillai, G. Sakoulas, C. Wennersten, L. Venkataraman, P. C. DeGirolami, G. M. Eliopoulos, R. C. Moellering, Jr., and H. S. Gold. 2004. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J. Infect. Dis. 190:311-317.
27. Meselson, M., J. Guillemin, M. Hugh-Jones, A. Langmuir, I. Popova, A. Shelokov, and O. Yampolskaya. 1994. The Sverdlovsk anthrax outbreak of 1979. Science 266:1202-1208.
28. Meyerhoff, A., and D. Murphy. 2002. Guidelines for treatment of anthrax. JAMA 288:1848.
29. Mikesell, P., B. E. Ivins, J. D. Ristroph, and T. M. Dreier. 1983. Evidence for plasmid-mediated toxin production in Bacillus anthracis. Infect. Immun. 39: 371-376.
30. National Committee of Clinical and Laboratory Standards. 1999. Document M26-A. Methods for determining bactericidal activity of antimicrobial agents: approved guidelines. National Committee of Clinical and Laboratory Standards, Wayne, PA.
31. Physicians' Desk Reference. 2007. Physician's desk reference, 61st ed., p.2652-2660. Thomson PDR, Montvale, NJ.
32. Pillai, S. K., G. Sakoulas, C. Wennersten, G. M. Eliopoulos, R. C. Moellering, Jr., M. J. Ferraro, and H. S. Gold. 2002. Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype. J. Infect. Dis. 186:1603-1607.
33. Rubinstein, E., R. Isturiz, C. Standiford, G. Smith, T. H. Oliphant, S. Cammarata, B. Hafkin, V. Le, and J. Remington. 2003. Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob. Agenls Chemother. 40:839-845.
34. Stevens, D. L., A. E. Bryant, and S. P. Hackett. 1995. Antibiotic effects on bacterial viability, toxin production, and host response. Clin. Infect. Dis. 20(Suppl. 2):S154-S157.
35. Stevens, D. L., A. E. Gibbons, R. Bergstrom, and V. Winn. 1988. The Eagle effect revisited: efficacy of clindamycin, erythromycin and penicillin in the treatment of streptococcal myositis. J. Infect. Dis. 158:23-28.
36. Stevens, D. L., Y. Ma, D. B. Salmi, E. McIndoo, R. J. Wallace, and A. E. Bryant. 2007. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 195:202-211.
37. Swaney, S. M., H. Aoki, M. C. Ganoza, and D. L. Shinabarger. 1998. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob. Agents Chemother. 42:3251-3255.
38. Tam, V. H., A. Louie, M. R. Deziel, W. Liu, R. Leary, and G. L. Drusano. 2005. Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. J. Infect. Dis. 192:420-428.
39. Zimbelman, J., A. Palmer, and J. Todd. 1999. Improved outcome of clindamycin compared with beta-laetam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr. Infect. Dis. J. 18:1096-1100.